Replies to post #242344 on Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

"You may want to reread this PR. FDA awarded Kevetrin Orphan Drug status for Ovarian cancer which means it’s far from dead."

Did YOU read it? That PR is almost two years old and was issued a year and a half after Kevetrin was awarded the Orphan Drug Designation.

Here's what Dr. B said in the 12/15/16 Press Release you linked:
“Based upon discussions with advisors and others with deep experience in this area, Cellceutix believes that an oral formulation of such a drug would command strong interest from large pharma, potentially resulting in a development partnership or investment.”
"The next step after obtaining the results of the supportive nonclinical studies will be to engage with the FDA pertaining to initiating a Phase 1 oral Kevetrin safety and toleration study in healthy volunteers as Kevetrin is non-cytotoxic. As is often the case with this type of study, Cellceutix anticipates that this type of trial could be completed in an expeditious fashion."

How'd that go?

Here's everything the Company said under Kevetrin for Ovarian Cancer in the PR from the day before yesterday:
"Next steps, building on our successful completed Phase 2a study in Ovarian Cancer, are planned to focus on completion of toxicology studies necessary for the oral formulation of Kevetrin and to prepare an appropriate oral dosage form to further evaluate the drug candidate’s clinical benefits and safety."

Just sleeping, like the Monty Python parrot.


"Btw-Your DD is terrible."
Wow.

[Snowy_Owl]

Kevetrin was granted orphan drug status for ovarian cancer (7/14/2015), pancreatic cancer (1/20/2016), and retinoblastoma (11/17/2015) and as far as I can tell this status is still in effect and will be for a few more years.

What may be perceived as a change in priority by some is labeled as "dead" by others. I'm in the priority category.

FDA awarded Kevetrin Orphan Drug status for Ovarian cancer which means it’s far from dead.